[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atrial-fibrillation-af\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atrial-fibrillation-af":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,213,0,25,[9,49,77,108,135,165,188,212,237,265,291,312,345,370,392,415,436,462,488,519,545,565,589,612,637],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100053313","phase-3-study-to-evaluate-the-efficacy-and-safety-of-abelacimab-in-high-risk-patients-with-atrial-fibrillation-who-have-been-deemed-unsuitable-for-oral-anticoagulation-lilac-timi-76-100053313",false,"NCT05712200","Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)","LILAC-TIMI 76","Inclusion Criteria:\n\n* Patient is able to understand and has provided written informed consent to participate in the trial\n* Diagnosed Atrial Fibrillation (AF) or atrial flutter (documented on an electrocardiogram (ECG) or monitor recording)\n* Age 65-74 and a CHA2DS2VASc ≥4 OR age ≥75 and a CHA2DS2VASc ≥3\n* Patient is judged by the responsible physician to be unsuitable for oral anticoagulation because the risks outweigh the benefits or the patient is unwilling to take oral anticoagulation AND this determination was made prior to and independent of the study\n* At least 1 bleeding risk factor such as severe renal insufficiency, planned daily use of antiplatelet medication for the duration of the trial, history of bleeding from a critical area, or other conditions associated with increased risk of bleeding such as chronic nonsteroidal anti-inflammatory drug (NSAID) use, frailty or multiple falls\n* Patient is judged by the responsible physician to be unsuitable for left atrial appendage (LAA) closure or occlusion device, an approved device is not available, or the patient is unwilling to undergo the procedure AND this determination was made prior to and independent of the study\n\nExclusion Criteria:\n\n* AF due to an ongoing acute reversible cause (e.g., cardiac surgery, pulmonary embolism (PE), untreated hyperthyroidism, alcohol use)\n* Patients who within 60 days prior to randomization (1) received a vitamin K antagonists (VKA) (e.g., warfarin, phenprocoumon, acenocoumarol) or a direct oral anticoagulant (DOAC) such as, dabigatran, rivaroxaban, apixaban, or edoxaban or (2) were newly diagnosed with AF\n* Patients with an intracranial or intraocular bleed within the 3 months prior to screening or any history of spontaneous intracerebral hemorrhage at any time in the absence of antithrombotic treatment\n* Any stroke within 14 days before randomization or transient ischemic attack (TIA) within 3 days before randomization\n* Mechanical heart valve or valve disease that is expected to require mechanical valve replacement intervention (surgical or invasive) during the course of the study\n* Patients on dialysis at screening or who are planned to start dialysis within 6 months\n\nOther protocol defined Inclusion\u002FExclusion criteria may apply","ALL","65 Years",{"count":21,"type":22},2500,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.",[28],"Atrial Fibrillation (AF)",[30,31,32,33,34,35],"abelacimab","randomized","placebo-controlled","double-blind","endpoint evaluation","atrial fibrillation","RECRUITING","2026-07-10",{"date":39,"type":40},"2026-07-13","ACTUAL",{"date":42,"type":40},"2022-12-27",{"date":44,"type":22},"2027-12-30",{"name":46,"class":47},"Anthos Therapeutics, Inc.","INDUSTRY",789,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100053980","comprehensive-left-atrial-appendage-occlusion-with-rhythm-restoration-100053980","NCT07523620","Comprehensive LEFt Atrial Appendage Occlusion With Rhythm Restoration","CLEAR","Inclusion Criteria:\n\n* Subject must provide written informed consent prior to any clinical investigation-related procedure.\n* 18 years of age or older, or the age of legal consent\n* CHA2DS2-VASc score of ≥ 3 for women and ≥ 2 for men\n* Able to stop anticoagulation by 90 days post index procedure\n* Able to adhere to the protocol defined post-concomitant procedure pharmacologic regimen of OAC for at least 60 days followed by SAPT\n* Plans to undergo a catheter ablation procedure including PVI due to symptomatic, recurrent, drug-refractory PAF or PersAF\n* Documented symptomatic PAF or PersAF. Documentation requirements are as follows:\n\nParoxysmal:\n\n* Physician's note indicating recurrent self-terminating AF with ≥ 2 episodes of PAF within the 12 months prior to enrollment AND\n* One electrocardiographically documented PAF episode within 12 months prior to enrollment.\n\nPersistent: Continuous AF sustained beyond 7 days and less than 1 year that is documented by\n\n* Physician's note, AND either\n* 24-hour Holter within 180 days prior to enrollment, showing continuous AF, OR\n* Two electrocardiograms (from any form of rhythm monitoring) showing continuous AF:\n\n  * That are taken at least 7 days apart but less than 12 months apart\n  * If electrograms are more than 12 months apart, there must be one or more Sinus Rhythm recordings in between or within 12 months prior to consent\u002Fenrollment\n  * The most recent electrocardiogram must be within 180 days of enrollment.\n\nNOTE: Documented evidence of the AF episode must either be continuous AF on a 12-lead ECG or include at least 30 seconds of continuous AF from another ECG device.\n\nExclusion Criteria:\n\n* Known contraindication or allergy to NOACs or aspirin, preventing use of the drugs post-procedure\n* Required to take P2Y12 platelet inhibitor after the study procedure (e.g., due to percutaneous coronary intervention)\n* Patients with heart prosthetic valves\n* Patient implanted with an inferior vena cava filter\n* Patients with left ventricular ejection fraction ≤30%\n* Patients with NYHA Class IV heart failure\n* Patients who have undergone any invasive intervention or surgery within 30 days prior to the index procedure (diagnostic catheterization is not within scope, however, percutaneous coronary intervention is within scope)\n* Patients who have experienced stroke or transient ischemic attack within 90 days prior to study procedure\n* Patients who have had previous attempt at LAA surgical or epicardial intervention (e.g., stapling, suturing, ligation, epicardial LAA management device)\n* Patients previously diagnosed long-standing persistent atrial fibrillation (Continuous AF greater than 1 year in duration)\n* Patients with arrhythmia due to reversible causes including thyroid disorders, acute alcohol intoxication, electrolyte imbalance, severe untreated sleep apnea, and other major surgical procedures within 90 days prior to the study procedure\n* Patients unable to receive heparin or an acceptable alternative to achieve adequate intra-procedural anticoagulation\n* Patients with a stent, constriction, or stenosis in a pulmonary vein\n* Patients with severe mitral regurgitation (regurgitant volume ≥ 60 mL\u002Fbeat, regurgitant fraction ≥ 50%, and\u002For effective regurgitant orifice area ≥ 0.40cm2)\n* Patients with severe renal failure (estimated glomerular filtration rate \\\u003C30 ml\u002Fmin\u002F1.73m2) or on chronic dialysis\n* Patients with severe pulmonary disease (e.g., restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces severe chronic symptoms\n* Patients with hypertrophic cardiomyopathy (maximal LV wall thickness ≥ 15 mm in the absence of abnormal loading conditions such as hypertension or aortic stenosis)","18 Years",{"count":58,"type":22},240,[60],"NA","The objective of this clinical investigation is to evaluate the feasibility, safety, and effectiveness of a concomitant procedure involving the Volt PFA System and Amulet 2 device in patients indicated for both AF ablation and percutaneous LAAO.",[28,63,64],"Paroxysmal AF","Persistent Atrial Fibrillation",[66,67,68,64],"Left Atrial Appendage","Atrial Fibrillation","Paroxysmal Atrial Fibrillation",{"date":39,"type":40},{"date":71,"type":40},"2026-03-31",{"date":73,"type":22},"2028-02-28",{"name":75,"class":47},"Abbott Medical Devices",16,{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":107},"100644942","atrial-remodeling-after-pfa-substrate-modification-for-persistent-af-peaf-100644942","NCT07675395","Atrial Remodeling After PFA Substrate Modification for Persistent AF (PeAF)","Pulsed-Field Ablation for Persistent Atrial Fibrillation: Impact of Atrial Remodeling After Substrate Modification","Inclusion Criteria:\n\n* Diagnosis of persistent atrial fibrillation\n* Left atrial anteroposterior (AP) diameter greater than 4 cm and less than 6 cm\n* Anti-arrhythmic medications (except amiodarone) discontinued for at least 5 half-lives before the procedure\n* No use of beta-blockers or diuretics before or after the ablation procedure\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Paroxysmal atrial fibrillation\n* Previous left atrial surgery or catheter ablation procedure, including left atrial appendage closure\n* Atrial fibrillation due to reversible causes, such as thyroid disorders, acute alcohol intoxication, or other major surgeries within the 90 days preceding the procedure\n* Myocardial infarction, acute coronary syndrome, percutaneous coronary intervention, or coronary artery bypass grafting within 90 days of the procedure\n* Known presence of cardiac thrombus\n* Stroke or transient ischemic attack within the last 90 days\n* Any other anatomical or comorbid condition that, in the investigator's opinion, could limit the patient's ability to participate in the clinical trial, comply with follow-up requirements, or impact the scientific validity of the clinical trial results",{"count":85,"type":22},30,[60],"Atrial fibrillation (AF) is associated with both electrical and structural remodeling of the left atrium. While successful catheter ablation has been shown to reverse some aspects of atrial remodeling, the impact of pulsed-field ablation (PFA) - a non-thermal ablation technology that selectively targets cardiomyocytes while sparing surrounding structures - on atrial remodeling in patients with persistent AF undergoing extensive substrate modification remains unclear.\n\nThis is a prospective, single-center, single-arm observational study conducted at Taipei Veterans General Hospital. The study will enroll 30 patients with persistent atrial fibrillation who undergo pulmonary vein isolation (PVI) and extensive substrate modification using the FARAWAVE \u002F FARADRIVE Catheter and FARASTAR System.\n\nThe primary objective is to evaluate left atrial structural remodeling following PFA, including changes in LA size, atrial strain, extent of atrial fibrosis, and atrial hemodynamic function. The secondary objective is to assess AF-free survival between 3 and 12 months after the procedure, and its relationship to atrial remodeling. All participants will be followed for 12 months, with an interim analysis conducted once all subjects complete their 6-month follow-up.",[64,28,89,90],"Atrial Remodeling","Pulsed Field Ablation",[90,64,67,89,92,93,94,95],"Substrate Modification","Atrial Fibrosis","Cardiac MRI","Posterior Wall Isolation","NOT_YET_RECRUITING","2026-06-30",{"date":99,"type":40},"2026-07-02",{"date":101,"type":22},"2026-07-01",{"date":103,"type":22},"2028-12-31",{"name":105,"class":106},"Taipei Veterans General Hospital, Taiwan","OTHER_GOV",1,{"id":109,"slug":110,"hasResults":12,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":23,"phases":118,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":134},"100607327","a-global-study-comparing-pulsed-field-ablation-with-electrographic-flow-mapping-versus-posterior-wall-ablation-for-persistent-atrial-fibrillation-100607327","NCT07187115","A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation","A Global Randomized Trial Comparing Pulsed Field Ablation of Pulmonary Veins Plus Extra-PV Sources Utilizing Electrographic Flow Mapping Versus Pulmonary Veins Plus Posterior Wall in Persistent Atrial Fibrillation Patients.","OPTIMIZE","Inclusion Criteria:\n\n1. ≥ 18 years of age, or older if required by local law\n2. Have symptomatic drug-refractory1, persistent AF2, confirmed by both:\n\n   * Documentation, such as physician note, of persistent continuous AF for \\> 7 days and ≤ 365 days and the arrhythmia symptoms\n   * Documentation, within 180 days of enrollment date of either:\n\n     * A 24-hour continuous ECG recording confirming continuous AF or\n     * Two (2) ECGs (from any regulatory cleared rhythm monitoring device) showing continuous AF taken at least 7 days apart\n3. Willing and capable of providing informed consent\n4. Willing and capable of participating in all follow-up assessments and testing associated with this clinical investigation at an approved clinical investigational center\n5. Willing to receive LUX-Dx™ insertable cardiac monitor (ICM) during the study or already has a LUX-Dx™ ICM that was inserted ≤ 6 months (i.e., within 180 days) of consent, and willing to comply to the LUX-Dx Latitude Clarity transmission instructions\n\nExclusion Criteria:\n\n1. Any of the following atrial conditions:\n\n   1. Left atrial anteroposterior diameter ≥ 5.5 cm, or if1 LA diameter not available, non-indexed volume \\>100 ml (physician note or imaging)\n   2. Any prior left atrial ablation\n   3. Any prior atrial surgery\n   4. Current atrial myxoma\n   5. Current left atrial thrombus\n   6. Any PV abnormality, stenosis, or stenting (common and middle PVs are admissible)\n2. Any of the following cardiovascular conditions:\n\n   1. History of sustained ventricular tachycardia or any ventricular fibrillation\n   2. Severe right ventricular dysfunction with documented echocardiography and\u002For hemodynamic data, per Investigator's discretion\n   3. AF that is secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible \u002F non-cardiac causes\n   4. Cardiac devices and implants:\n\n      * Current or anticipated pacemaker, implantable cardioverter defibrillator or cardiac resynchronization therapy devices\n      * Implantable loop recorder, other than LUX-Dx\n      * Interatrial baffle, patent foramen ovale or atrial septal defect closure device or patch\n      * Any left atrial appendage closure or occlusion device\n   5. Presence of any of the following valvular conditions:\n\n      * Any prosthetic heart valve, stenotic valves, ring or repair\n      * Moderate to severe mitral valve stenosis\n      * More than moderate mitral regurgitation\n   6. Hypertrophic or amyloid cardiomyopathy\n   7. Any IVC filter, known inability to obtain vascular access or other contraindication to femoral access\n   8. Awaiting cardiac transplantation or other planned cardiac surgery within the next 12 months\n   9. Severe right ventricular dysfunction with documented echocardiography and\u002For hemodynamic data.\n3. Any of the following conditions at Baseline:\n\n   1. Heart failure associated with NYHA Class III or IV\n   2. Most recent documented LVEF \\\u003C 40% within the previous 12 months\n   3. Body Mass Index (BMI) \\> 45.0\n   4. Known coagulopathy or bleeding disorder\n   5. Contraindication to, or unwillingness to use systemic anticoagulation, or acceptable alternatives, pre-, intra- and post-procedure to achieve adequate anticoagulation\n   6. Women who are confirmed to be pregnant or lactating at the time of the ablation procedure\n   7. Severe lung disease, severe pulmonary hypertension, or any lung disease involving abnormal blood gases or requiring supplemental oxygen\n   8. Active malignancy (other than squamous cell carcinoma)\n   9. Clinically significant gastrointestinal problems involving the esophagus or stomach including severe or erosive esophagitis, uncontrolled gastric reflux, gastroparesis, esophageal candidiasis or active gastroduodenal ulceration\n   10. Known active systemic infection\n   11. Untreated diagnosed obstructive sleep apnea with apnea hypopnea index classification of severe (\\>30 pauses per hour) as per the guidelines\n   12. Predicted life expectancy less than one year per investigator medical judgement\n   13. Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments; each instance must be brought to the attention of the Sponsor to determine eligibility\n   14. Required use of phosphodiesterase inhibitors within 24 hours of the ablation procedure\n   15. Uncontrolled hypertension (SBP \\> 160 mmHg or DBP \\> 95 mmHg on two (2) BP measurements at baseline assessment not attributable to white coat syndrome per Investigator opinion\n   16. CHA2DS2-VASc score ≥ 5\n   17. Known allergic drug reaction to nitroglycerin (excluding hypotension)\n   18. Unwillingness to receive, or unable to tolerate, a subcutaneous, chronically inserted LUX-Dx ICM device\n4. Any of the following congenital conditions:\n\n   1. Congenital heart disease with any clinically significant residual anatomic or conduction abnormality\n   2. History of known congenital methemoglobinemia\n   3. History of known G6PD deficiency\n5. Any of the following conditions in the medical history:\n\n   1. Solid organ or hematologic transplant, or currently being evaluated for a transplant\n   2. Any prior history or current evidence of hemi-diaphragmatic paralysis or paresis\n   3. Any documented history of Prinzmetal Angina or severe non-revascularizable coronary disease\n   4. Renal insufficiency if an estimated glomerular filtration rate (eGFR) is \\\u003C 30 mL \u002F min \u002F 1.73 m2, or with any history of renal dialysis or renal transplant\n   5. Any other general health condition that, in the investigator's medical opinion, would prevent participation in the study, interfere with assessment or therapy, significantly raise the risk of study participation, or modify outcome data or its interpretation.\n6. Any of the following events less than or equal to 90 days of the consent date:\n\n   1. Myocardial infarction (MI), unstable angina or coronary intervention\n   2. Any cardiac surgery\n   3. Heart failure hospitalization\n   4. Pericarditis or symptomatic pericardial effusion\n   5. Gastrointestinal bleeding\n   6. Stroke, TIA, or intracranial bleeding\n   7. Any active non-neurologic thrombus and\u002For thromboembolic event\n   8. Carotid stenting or endarterectomy\n   9. Uncontrolled diabetes mellitus or a recorded HbA1c \\> 8.0%",{"count":117,"type":22},699,[60],"The purpose of this study is to establish the safety of the pulsed field ablation (PFA) therapy of Pulmonary Veins and Electrographic Flow (EGF) identified extra-PV sources of atrial fibrillation (PVI + EGF ablation of sources) and to demonstrate its non-inferiority in effectiveness compared to PFA of Pulmonary Veins and LA Posterior Wall (PVI+ PWA) in the treatment of de novo symptomatic drug-refractory persistent atrial fibrillation (PersAF).",[28,121],"Persistant Atrial Fibrillation",[123,124,125],"FARAPULSE","FARAPOINT","OptiMap","2026-06-29",{"date":97,"type":40},{"date":129,"type":40},"2025-11-07",{"date":131,"type":22},"2030-12",{"name":133,"class":47},"Boston Scientific Corporation",42,{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":23,"phases":145,"briefSummary":146,"conditions":147,"keywords":152,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":164},"100619784","option-emea-clinical-trial-100619784","NCT07349121","OPTION-EMEA Clinical Trial","Concomitant Left Atrial Appendage Closure and Pulsed Field Ablation - Europe, Middle East and Africa [OPTION-EMEA]","OPTION-EMEA","Inclusion Criteria:\n\n1. Clinically indicated for treatment with both the FARAPULSE™ PFA system and with WATCHMAN FLX™ Pro or WATCHMAN FLX™ for LAAC, per physician medical judgement and as per hospitals' standard of care.\n2. Subjects who are willing and able to provide informed consent.\n3. Subjects who are willing and able to participate in all testing associated with this clinical study at an approved investigational center.\n4. Subjects whose age is 18 years or above, or who are of legal age to give informed consent specific to state and national law.\n\nExclusion Criteria:\n\n1. Subjects who underwent prior AF ablation procedure.\n2. Subjects with atrial fibrillation that is secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible \u002F non-cardiac causes.\n3. Already surgically closed or otherwise excluded LAA.\n4. The LAA anatomy does not accommodate a Closure Device.\n5. Known or suspected atrial myxoma.\n6. Presence of intracardiac thrombus\\*.\n7. Subjects with a current interatrial baffle or patch, history of atrial septal repair or has an atrial septal defect (ASD) \u002F patent foramen ovale (PFO) device.\n8. Subjects with a presence of a mechanical valve prosthesis in any position.\n9. Subjects with a myocardial infarction within 90 days prior to enrollment.\n10. Subjects had a prior stroke (of any cause, whether ischemic or hemorrhagic) or transient ischemic attack (TIA) within 90 days prior to enrollment.\n11. Any planned electrical cardioversion within 30 days following LAAC device implant.\n12. Subjects with a known inability to obtain vascular access.\n13. Subjects with any contraindication to percutaneous catheterization procedure (e.g., patient size does not accommodate required catheters, ventriculotomy or atriotomy) or congenital abnormalities (severe rotational anomalies of the heart or great vessels) are present.\n14. Subjects with any active conditions (e.g. infection, bleeding disorder, unstable angina).\n15. Subjects with any contraindications to short term use of anticoagulation therapy for conditions different from atrial fibrillation.\n16. Subjects who are pregnant or planning to be pregnant.\n17. Subjects with a life expectancy of ≤ 1 year per investigator's opinion.\n18. Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments. Each instance must be reviewed by the sponsor to determine eligibility.",{"count":144,"type":22},500,[60],"The OPTION-EMEA post-market study is intended to gather real world clinical data for patients undergoing AF ablation with the FARAPULSE™ Pulsed Field Ablation (PFA) System and subsequent left atrial appendage closure (LAAC) with a WATCHMAN FLX™ Pro or WATCHMAN FLX device during one interventional case.\n\nThe study will include patients that are clinically indicated for atrial fibrillation (AF) ablation using the FARAPULSE PFA System and for left atrial appendage closure (LAAC) treatment using a WATCHMAN FLX Pro or WATCHMAN FLX device as part of the patient's standard of care determined by their doctor's medical judgement.",[28,148,149,90,150,151],"Stroke Prevention in Patients With Atrial Fibrillation","Left Atrial Appendage Closure","Atrial Fibrillation Ablation Procedure","Concomitant Procedures",[153,123,154,155,156],"WATCHMAN","Concomitant","PFA","LAAC","2026-06-26",{"date":97,"type":40},{"date":160,"type":40},"2026-06-18",{"date":162,"type":22},"2029-12",{"name":133,"class":47},3,{"id":166,"slug":167,"hasResults":12,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":173,"targetDuration":175,"studyType":176,"phases":4,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":164},"100644634","bodyguardian-monitoring-for-recurrence-of-af-100644634","NCT07671677","BOdygUardian MOnitoriNg for ReCurrencE of AF","BOdygUardian MOnitoriNg for ReCurrencE of AF (BOUNCE-AF)","BOUNCE-AF","Patients must meet all the following criteria to be eligible for inclusion in the BOUNCE-AF sub-study:\n\n1. Eligible for and willing to consent for participation in DISRUPT-AF\n2. Willing to consent to the sub-study\n3. Willing to complete the post-ablation BodyGuardian wearable monitoring\n4. Willing to complete the BOUNCE AF survey\n\nClinical staff willing to consent to complete surveys must meet one of the following requirements:\n\n1. Prescribe the monitor by enrolling patients into the BodyGuardian platform.\n2. Review monitor data using the BodyGuardian platform.\n\nExclusion Criteria:\n\n1\\. Known allergy to adhesives that would contraindicate wearing BodyGuardian",{"count":174,"type":22},100,"6 Months","OBSERVATIONAL","The DISRUPT-AF Registry is an observational, prospective, multi-center, non-randomized, real-world registry designed to obtain clinical experience with the FARAPULSE Pulsed Field Ablation (PFA) System for the treatment of atrial fibrillation (AF). The data collected for this study will be from a subset of patients enrolled in the pre-existing DISRUPT AF Registry. Additionally, patients in the Full Monitoring Arm may be approached and consented for participation in BOUNCE-AF. The post-ablation monitoring timepoints will reflect the site's standard of care (SOC), which is typically at 6- and 12-months post-ablation. Consented patients will complete 1 survey about their experience after wearing the BodyGuardian at 6-months. Clinical staff that consent will also complete a survey on their experience using BodyGuardian. The clinical staff include those that either directly prescribe the monitor, place the monitor on the patient and\u002For train the patient on the use of the monitor, or those involved in reviewing the data.",[28],"2026-06-23",{"date":157,"type":40},{"date":182,"type":22},"2026-07",{"date":184,"type":22},"2028-04",{"name":186,"class":187},"Heart Rhythm Clinical and Research Solutions, LLC","OTHER",{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":23,"phases":198,"briefSummary":199,"conditions":200,"keywords":201,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":206,"startDateStruct":207,"completionDateStruct":208,"leadSponsor":210,"locationsCount":107},"100634723","nudging-for-anticoagulation-adherence-in-atrial-fibrillation-100634723","NCT07543393","Nudging for Anticoagulation Adherence in Atrial Fibrillation","The Effects of Nudging Intervention in Promoting Adherence to Anticoagulation Among Patients With Atrial Fibrillation: a Randomized Controlled Trail","NUDGE-AF","Inclusion Criteria:\n\n* Age ≥18 years\n\nDiagnosed with non-valvular atrial fibrillation (AF) confirmed by medical records\n\nPrescribed oral anticoagulants (e.g., warfarin, rivaroxaban, apixaban, dabigatran, edoxaban) for at least 3 months\n\nOwn a personal mobile phone capable of receiving SMS messages\n\nWilling and able to provide written informed consent\n\nExclusion Criteria:\n\n* Severe cognitive impairment or psychiatric disorder that would preclude completion of questionnaires or adherence to the intervention\n\nLife expectancy \\\u003C6 months due to comorbid conditions\n\nCurrently enrolled in another medication adherence intervention study\n\nUnable to read or understand Chinese (since validated Chinese scales are used)",{"count":197,"type":22},84,[60],"The goal of this clinical trial is to learn if a nudging intervention (using text message reminders, a medication calendar, and action planning) can help people with atrial fibrillation take their blood-thinning medication (anticoagulants) as prescribed.\n\nThe main questions it aims to answer are:\n\nDoes the nudging intervention improve medication adherence compared to usual care?\n\nHow does the intervention affect patients' beliefs about their medication and the automaticity of pill-taking?\n\nIs the intervention cost-effective?\n\nResearchers will compare participants who receive the nudging intervention with those who receive usual care.\n\nParticipants will:\n\nWatch a short educational video about atrial fibrillation and stroke prevention\n\nMake a personal plan to take their medication at the same time each day (for example, after breakfast)\n\nReceive text message reminders 1 to 3 times per week, with fewer messages over time\n\nGet a medication calendar to track daily doses\n\nAnswer a few questionnaires at the start, at 8 weeks, and at 12 weeks",[28],[202,203,204,67,205],"Nudge","Medication Adherence","Anticoagulation","Randomized Controlled Trial",{"date":157,"type":40},{"date":97,"type":22},{"date":209,"type":22},"2027-02-20",{"name":211,"class":187},"Sun Yat-sen University",{"id":213,"slug":214,"hasResults":12,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":176,"phases":4,"briefSummary":222,"conditions":223,"keywords":225,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":107},"100616940","isolation-of-pulmonary-veins-using-the-box-technique-in-patients-undergoing-sternotomy-100616940","NCT07312149","Isolation of Pulmonary Veins Using the Box Technique in Patients Undergoing Sternotomy","BoxTer : Isolation of Pulmonary Veins Using the Box Technique in Patients Undergoing Sternotomy","BoxTer","Inclusion criteria:\n\n* Patients undergoing cardiac surgery via sternotomy\n* Concomitant use of the PWI box with GeminiS during surgery\n* Adult patients\n* Patients with the following characteristics: Preoperative paroxysmal\u002Fpersistent\u002Fpermanent AF; Duration of less than 5 years; And left atrium volume \\\u003C60 ml\u002Fm2\n* Informed patient who did not object to the collection of their data for the study\n\nExclusion criteria:\n\n* Unplanned surgery (emergency)\n* History of cardiac surgery (reoperation)\n* Pregnant or breastfeeding women\n* Adults under guardianship, curatorship or judicial protection\n* Patients with a life expectancy of less than three years\n* Patients currently taking medication or using an experimental device that clinically interferes with the study's evaluation criteria and results.\n* Inability to comply with the monitoring schedule.\n* Contraindication to long-term anticoagulants",{"count":221,"type":22},200,"Atrial Fibrillation (AF) is the most common cardiac arrhythmia worldwide, affecting approximately 2.8% of the population, with prevalence increasing with age. AF is associated with significant morbidity and mortality, accounting for about 25% of ischemic strokes, 10% of cryptogenic strokes, and a 10-40% annual increase in hospital admissions due to heart failure or anticoagulant-related events.\n\nAbout 10% of patients undergoing cardiac surgery have preoperative AF. In 1986, Dr. Cox introduced the MAZE procedure, a surgical technique to isolate AF triggers. Initially involving atrial incisions, it evolved to use radiofrequency lines, significantly reducing morbidity and mortality. The MAZE procedure is now strongly recommended (Class Ia evidence) for concomitant cardiac surgery. However, nearly 85% of eligible patients-especially those undergoing closed-chest cardiac surgery-do not receive this treatment due to technical challenges and limited reproducibility of the Cox-Maze IV technique.\n\nPulmonary Vein Isolation (PVI) with posterior wall isolation (PWI-Box) has emerged as an effective alternative, offering similar outcomes to Cox-Maze IV with fewer adverse effects. Innovative devices like the GeminiS (Medtronic) enable minimally invasive, thoracoscopic PVI-PWI-Box procedures without opening the heart, even off-pump. This approach could expand the use of AF ablation during combined sternotomy surgeries, aligning with clinical guidelines.\n\nPrimary Objective: Assess the efficacy of PWI-Box using GeminiS combined with other cardiac surgeries via sternotomy.\n\nPrimary Endpoint: Recurrence rate of paroxysmal or persistent AF (per ESC definition) at 1 year postoperatively, confirmed by 24-hour Holter monitoring.",[28,224],"Cardiac Surgery",[226,224,227,228],"Atrial firbrillation","PWI-Box","GeminiS",{"date":230,"type":40},"2026-06-24",{"date":232,"type":22},"2026-10-05",{"date":234,"type":22},"2032-10-05",{"name":236,"class":187},"Nantes University Hospital",{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":23,"phases":247,"briefSummary":248,"conditions":249,"keywords":250,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":264},"100626078","phase-3-stroke-and-systemic-embolism-prevention-in-adult-participants-with-atrial-fibrillation-for-whom-oral-anticoagulation-is-unsuitable-100626078","NCT07430956","Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable","A Master Protocol for a Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention With REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, Versus Placebo in Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable (ROXI-INCLINE)","ROXI-INCLINE","Key Inclusion Criteria:\n\n1. Has AF or flutter (paroxysmal or persistent), not considered to be secondary to a reversible cause\n2. At moderate to high risk for stroke defined as:\n\n   1. CHA2DS2-VA \\[C: Congestive heart failure; H: Hypertension; A2: Age ≥75 years (double points); D: Diabetes mellitus; S2: Stroke or TIA or Systemic embolism (double points); V: Vascular disease; A: Age 65-74 years\\] score ≥4 OR\n   2. CHA2DS2-VA score of 3 AND at least 1 enrichment criteria as described in the protocol\n3. Shared decision making between the participant and provider determining that the bleeding risk of Oral Anticoagulant (OAC) therapy outweighs the benefits, making the participant unsuitable for OAC therapy as described in the protocol\n\nKey Exclusion Criteria:\n\n1. Has a mechanical heart valve prosthesis (Note: transcatheter aortic valve replacement is not an exclusion)\n2. Had an ischemic stroke within 2 days prior to randomization\n3. Has persistent, uncontrolled hypertension (per investigator's discretion)\n4. Has a history of Central Nervous System (CNS) bleeding within 30 days prior to randomization\n5. Has a life expectancy less than 12 months\n6. Has participated in a prior Factor XI (FXI) inhibitor study\n\nNote: Other protocol-defined Inclusion\u002F Exclusion criteria apply",{"count":246,"type":22},2628,[25],"This study is researching 2 different experimental drugs called REGN7508 and REGN9933 (called \"study drugs\"). The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly. When this happens, blood cannot move smoothly through the heart; it can slow down or pool in one spot, which can lead to the formation of blood clots.\n\nREGN7508 and REGN9933 are designed to help stop blood clots forming in patients with atrial fibrillation. The aim of the study is to see how effective and safe REGN7508 and REGN9933, individually, are in preventing ischemic stroke or systemic embolism in people with atrial fibrillation who cannot or may choose to not take blood thinners.\n\nThe study is looking at several other research questions, including:\n\n* What side effects may happen from taking REGN7508 or REGN9933\n* How well does REGN7508 or REGN9933 lower the risk of having an ischemic stroke and\u002For systemic embolism compared to the placebo\n* How well does REGN7508 or REGN9933 lower the risk of having a major health problem affecting heart and blood circulation compared to placebo\n* How well does REGN7508 or REGN9933 lower the risk of death compared to placebo\n* How much REGN7508 or REGN9933 is in the blood at different times\n* Whether the body makes antibodies against REGN7508 or REGN9933 (which could make the study drugs less effective or could lead to side effects)",[28],[251,252,253,254,255],"Blood clots","Ischemic stroke","Systemic embolism","Pulmonary embolism","Venous Thromboembolism (VTE)","2026-06-22",{"date":179,"type":40},{"date":259,"type":40},"2026-04-03",{"date":261,"type":22},"2029-06-26",{"name":263,"class":47},"Regeneron Pharmaceuticals",18,{"id":266,"slug":267,"hasResults":12,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":23,"phases":275,"briefSummary":277,"conditions":278,"keywords":279,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":290},"100606428","phase-2-safety-in-adult-participants-with-atrial-fibrillation-who-are-treated-with-anticoagulation-100606428","NCT07175428","Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation","A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS)","ROXI-ATLAS","Key Inclusion Criteria:\n\n1. Has AF or flutter (paroxysmal or persistent), not felt to be secondary to a reversible cause, and an indication for indefinite anticoagulation treatment as described in the protocol\n2. Meets one of the following:\n\n   1. CHA2DS2-VA \\[C: Congestive heart failure; H: Hypertension; A2: Age ≥75 years (double points); D: Diabetes mellitus; S2: Stroke or TIA or Thromboembolism (double points); V: Vascular disease; A: Age 65-74 years\\] score ≥2 and Oral Anticoagulant (OAC) naïve or\n   2. CHA2DS2-VA score ≥3 or\n   3. CHA2DS2-VA score of 2 and at least 1 enrichment criteria as described in the protocol\n3. Must have an International Normalization Ratio (INR) \\\u003C2.5 at the time of randomization if taking warfarin or another Vitamin K Antagonist (VKA)\n\nKey Exclusion Criteria:\n\n1. Has a mechanical heart valve prosthesis (Note: transcatheter aortic valve replacement is not an exclusion)\n2. Has known moderate-to-severe mitral stenosis\n3. Has had successful ablation therapy or Left Atrial Appendage (LAA) occlusion\u002Fexclusion, or planned ablation or LAA occlusion\u002Fexclusion as described in the protocol\n4. Had an ischemic stroke within 2 days prior to randomization\n5. Has estimated Glomerular Filtration Rate (eGFR) \\\u003C15 mL\u002Fmin\u002F1.73m\\^2 within 30 days prior to randomization or on dialysis or expected to be started as described in the protocol\n6. Has a history of central nervous system bleeding within 30 days prior to randomization\n\nNote: Other protocol-defined Inclusion\u002F Exclusion criteria apply",{"count":274,"type":22},1200,[276],"PHASE2","This study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which means that the heart beats too fast and unevenly. REGN7508 and REGN9933 are designed to help stop blood clots forming in patients with atrial fibrillation.\n\nThe aim of the study is to see how well REGN7508 and REGN9933 work in patients that get medicine for their atrial fibrillation. The bleeding effects of REGN7508 and REGN9933 will be compared to another medicine (apixaban), which is available on the market to treat and prevent formation of blood clots.\n\nThe study is looking at several other research questions, including:\n\n* What side effects may happen from taking REGN7508 or REGN9933\n* How well do the study drugs reduce the risk of having a stroke\n* How much of REGN7508 or REGN9933 is in the blood at different times\n* Whether the body makes antibodies against REGN7508 or REGN9933 (which could make the drugs less effective or could lead to side effects)",[28],[280,281,253,251],"Bleeding","Stroke","2026-06-16",{"date":284,"type":40},"2026-06-17",{"date":286,"type":40},"2025-10-20",{"date":288,"type":22},"2027-04-21",{"name":263,"class":47},48,{"id":292,"slug":293,"hasResults":12,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":297,"eligibilityCriteria":298,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":299,"enrollmentInfo":300,"targetDuration":4,"studyType":23,"phases":301,"briefSummary":302,"conditions":303,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":107},"100642887","unipolar-voltage-mapping-for-personalized-atrial-fibrillation-ablation-100642887","NCT07630857","Unipolar Voltage Mapping for Personalized Atrial Fibrillation Ablation","Unipolar Mapping for Personalized Atrial Fibrillation Ablation: An Interventional Study on Arrhythmia Maintenance and Atrial Remodeling","UNIQS-AF","Inclusion Criteria:\n\n* Age ≥ 18 years and ≤ 80 years\n* Documented diagnosis of atrial fibrillation (paroxysmal or persistent)\n* Planned to undergo catheter ablation for AF (including patients with recurrent AF after prior ablation)\n* Able and willing to provide written informed consent\n* Able to complete scheduled follow-up visits (3 months post-ablation)\n\nExclusion Criteria:\n\n* Left ventricular ejection fraction \\\u003C 35%\n* Severe valvular heart disease (moderate to severe mitral stenosis or regurgitation)\n* History of intracardiac thrombus\n* Contraindication to anticoagulation\n* Active infection or sepsis\n* Pregnancy or breastfeeding\n* Life expectancy \\\u003C 12 months due to comorbid conditions\n* Participation in another interventional clinical trial within 30 days prior to enrollment","80 Years",{"count":221,"type":22},[60],"Atrial fibrillation (AF) is a common heart rhythm disorder. While catheter ablation is an effective treatment, many patients still experience AF recurrence after the procedure. One major reason is that the mechanisms that maintain AF are not fully understood. Research suggests that the outer layer of the heart (epicardium) may play an important role in keeping AF going. However, current mapping techniques have limitations in detecting electrical signals from both the inner and outer heart layers.\n\nThis study uses a different technique called unipolar voltage mapping, which may more accurately capture electrical signals from both heart layers. Specifically, we focus on a specific type of electrical signal called \"QS potential\" on unipolar mapping, which reflects breakthrough sites between the inner and outer heart layers.\n\nIn this interventional study, participants with AF undergoing catheter ablation will receive personalized ablation guided by unipolar QS-potential mapping. We aim to:\n\nExplore the relationship between unipolar QS-potentials and AF maintenance and atrial remodeling Evaluate the effectiveness of QS-potential guided personalized AF ablation",[28],"2026-06-15",{"date":282,"type":40},{"date":307,"type":22},"2026-06-20",{"date":309,"type":22},"2026-12-20",{"name":311,"class":106},"China National Center for Cardiovascular Diseases",{"id":313,"slug":314,"hasResults":12,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":320,"enrollmentInfo":321,"targetDuration":4,"studyType":23,"phases":323,"briefSummary":324,"conditions":325,"keywords":331,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":344},"100627110","start-cpap-therapy-in-obstructive-sleep-apnea-patients-after-atrial-fibrillation-ablation-100627110","NCT07444372","Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation","Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation: A Multicenter, Open-label, Randomized Clinical Trial","STOP-AFib","Inclusion Criteria:\n\nPatients must meet all of the following conditions to be eligible for the study:\n\n* Age 18-75 years.\n* Patients with persistent AF scheduled for first-time catheter ablation.\n* Diagnosed with OSA.\n* Able to tolerate CPAP therapy.\n* Capable of understanding and complying with the study protocol.\n* Willing to sign the informed consent form.\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria will be excluded from the study:\n\n* Secondary AF.\n* Left atrial anteroposterior diameter 60mm (measured via parasternal long-axis view).\n* Left ventricular ejection fraction \\\u003C 30%.\n* Comorbid moderate-to-severe mitral stenosis or history of prosthetic valve replacement (mechanical or bioprosthetic).\n* Pregnant or breastfeeding women.\n* History of myocardial infarction, percutaneous coronary intervention, or cardiac surgery within 3 months prior to screening.\n* History of stroke or transient ischemic attack within 6 months prior to screening.\n* Perioperative complications related to the ablation procedure occurring prior to randomization.\n* Inability to discontinue antiarrhythmic drugs (AADs) post-procedure due to other reasons.\n* Life expectancy \\\u003C 1 year.\n* Central sleep apnea.\n* Conditions requiring ventilatory support, including obesity hypoventilation syndrome (defined as BMI \\> 30kg\u002Fm² and awake PaCO₂ \\> 45mmHg), amyotrophic lateral sclerosis, or chronic obstructive pulmonary disease with \\> 1 episode of respiratory failure or hypercapnia.\n* Treatment-emergent central sleep apnea during CPAP tolerance assessment that cannot be corrected prior to randomization.\n* Receipt of instrumental or surgical treatment for OSA within 3 months prior to screening, including CPAP, oral appliances, ENT surgery, or bariatric surgery.\n* Use of glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide receptor agonists, or glucagon receptor agonists for weight loss within 3 months prior to screening, or plans to initiate such medications within the next year.\n* Current participation in other drug or device trials.","75 Years",{"count":322,"type":22},658,[60],"Atrial fibrillation (AF) is one of the most common clinical arrhythmias. Catheter ablation is an effective therapeutic strategy; however, recurrence rates remain substantial, ranging from 20% to 45%. Previous studies have established a strong association between obstructive sleep apnea (OSA) and the risk of AF recurrence following ablation. While continuous positive airway pressure (CPAP) is the standard intervention for OSA, and some observational studies suggest it may reduce post-ablation recurrence in patients with comorbid OSA, small randomized controlled trials have failed to confirm a clear benefit, potentially due to poor adherence.\n\nThis study aims to evaluate the clinical benefit of post-ablation CPAP therapy in AF patients with comorbid OSA.\n\nParticipants will:\n\n* Be randomly assigned to either the CPAP group or the usual care group.\n* If in the CPAP group, use a CPAP device for 12 months.\n* Wear an ambulatory ECG recorder for a 7-day period at 3, 6, 9, and 12 months post-operation.\n* Complete follow-up checkups either at the clinic or over the phone at 1, 3, 6, and 12 months after their procedure.",[326,327,28,328,329,330],"Obstructive Sleep Apnea","Sleep Disorder (Disorder)","Sleep Disordered Breathing (SDB)","Arrhythmia","Continuous Positive Airway Pressure",[326,330,67,332,333,334,335],"Ablation of atrial fibrillation","Sleep Disordered Breathing","Clinical Trial","Catheter Ablation","2026-06-14",{"date":282,"type":40},{"date":339,"type":40},"2026-05-12",{"date":341,"type":22},"2029-01-31",{"name":343,"class":187},"Beijing Anzhen Hospital",27,{"id":346,"slug":347,"hasResults":12,"nctId":348,"briefTitle":349,"officialTitle":349,"acronym":350,"eligibilityCriteria":351,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":352,"targetDuration":4,"studyType":176,"phases":4,"briefSummary":354,"conditions":355,"keywords":356,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":107},"100589183","mechanisms-of-myocardial-injury-and-ischemia-in-patients-with-rapid-atrial-fibrillation-100589183","NCT06951100","Mechanisms of Myocardial Injury and Ischemia in Patients With Rapid Atrial Fibrillation","Mi-AF","Inclusion Criteria:\n\n1. Age 18 years and over\n2. Primary presentation with symptoms related to atrial fibrillation\n3. Atrial fibrillation with a ventricular rate \\>100 bpm on a 12-lead electrocardiogram\n4. Able to provide informed consent\n\nExclusion Criteria\n\n1. Previous myocardial infarction\n2. Previous coronary revascularisation procedure\n3. Patients in renal failure (eGFR \\\u003C30ml\u002Fmin\u002F1.73m2) or major allergy to contrast media\n4. Pregnancy or breast feeding\n5. Deemed unsuitable for participation in the study by the attending clinician\n6. Previous enrolment in the trial",{"count":353,"type":22},300,"The goal of this observational study is to better understand the role of measuring troponin (a protein measured by a blood test) and coronary imaging in patients presenting with rapid atrial fibrillation (AF)\n\nThe main questions this study aims to answer are:\n\n1. Are patients with a fast, irregular heartbeat (rapid AF) and damage to the heart (myocardial injury) more likely than those without damage to the heart to have blocked heart arteries (obstructive coronary artery disease)\n2. Are patients with a fast, irregular heartbeat (rapid AF) and damage to the heart (myocardial injury) with further evidence that their heart hasn't been getting enough oxygen (myocardial ischemia) more likely to have imaging evidence of myocardial infarction than those without myocardial ischemia\n\nTo do this, we will measure troponin in patients with rapid AF and then carry out further investigations of the heart (electrocardiogram, echocardiogram, CT scan and cardiac MRI)",[28],[67,357,358,359,360,361],"Cardiology","Emergency Medicine","Myocardial Infarction","Myocardial Ischemia","Coronary Artery Disease","2026-06-12",{"date":304,"type":40},{"date":365,"type":40},"2025-05-01",{"date":367,"type":22},"2029-10",{"name":369,"class":187},"University of Edinburgh",{"id":371,"slug":372,"hasResults":12,"nctId":373,"briefTitle":374,"officialTitle":374,"acronym":375,"eligibilityCriteria":376,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":377,"targetDuration":4,"studyType":176,"phases":4,"briefSummary":379,"conditions":380,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":387,"completionDateStruct":388,"leadSponsor":390,"locationsCount":107},"100642550","association-between-circulating-bdnf-levels-and-atrial-cardiomyopathy-in-patients-undergoing-ablation-for-persistent-atrial-fibrillation-100642550","NCT07648329","Association Between Circulating BDNF Levels and Atrial Cardiomyopathy in Patients Undergoing Ablation for Persistent Atrial Fibrillation","METAPROFIL 2","Inclusion Criteria:\n\n* Participants who have provided written consent\n* Patients aged 18 years or older.\n* Patients scheduled to undergo their first ablation procedure for persistent atrial fibrillation at the Dijon Bourgogne University Hospital\n\nExclusion Criteria:\n\n* A person who is not enrolled in or eligible for a social security program\n* A person subject to a legal protective measure (guardianship, conservatorship)\n* Person subject to a judicial safeguard measure\n* Pregnant or breastfeeding woman\n* Adult who is legally incapacitated or unable to give consent\n* Ablation of paroxysmal AF with or without electroanatomical mapping",{"count":378,"type":22},150,"trial fibrillation (AF) is the most common cardiac arrhythmia worldwide, and its prevalence continues to rise. AF is associated with serious complications, including embolic strokes, heart failure, and mortality. Characterized by rapid, irregular, and weakened contractions of the atria, AF is considered one of the \"visible\" electrophysiological manifestations of a broader condition known as atrial cardiomyopathy (ACM). Disruption of normal blood flow in the atrium, particularly in the context of an endocardium predisposed to thrombosis, predisposes to thrombus formation. Once dislodged from the atrial cavity and migrating to the cerebral arteries, these thrombi can cause a cardioembolic stroke. The main risk factors for ACI\u002FAF are metabolic syndrome and aging. CMA is a condition that is difficult to diagnose because it is not clearly defined, except through histological analysis. Guided by the results of our experimental approaches, we aim to address this challenge by approaching CMA through one of its complications: persistent atrial fibrillation. Indeed, CMA can be assessed using electroanatomical mapping during atrial fibrillation ablation (AFA) procedures. During radiofrequency ablation of AF, electroanatomical mapping of the left atrium is performed to measure left atrial voltage, which serves as an indirect marker of the presence of atrial fibrosis, strongly associated with CMA. Other parameters relevant to the identification of CMA can be assessed during this procedure, such as conduction velocities and specific electrographic characteristics.\n\nWe plan to include 150 patients undergoing ablation for persistent atrial fibrillation at the Dijon Bourgogne University Hospital and to correlate circulating levels of BDNF (brain-derived neurotrophic factor) with electroanatomical mapping data of the left atrium. The electrical remodeling of the left atrium, including low-voltage areas and conduction velocity, as well as left atrial morphology assessed by pre-procedural cardiac computed tomography using the ADAS3 Galgo LA Module software, will be correlated with BDNF levels. Blood samples for BDNF assessment will be collected before or at the start of the ablation procedure, prior to any catheter insertion into the vessels.\n\nWhile investigating the association between BDNF levels and CMA characteristics during AF ablation, thereby confirming the pathophysiological relationship with atrial remodeling, our objective is also to evaluate the prognostic role of BDNF levels in clinical and rhythm outcomes following AF ablation. Thus, we will compare changes in BDNF levels after AF ablation at one-year follow-up, correlating them with the evolution of CMA-based on left atrial parameters assessed by echocardiography or cardiac computed tomography-autonomic nervous system balance and heart rhythm obtained via Holter monitoring, as well as clinical outcomes.",[28,381,382,383,384],"Cardiac Arrhythmia","Atrial Fibrillation Ablation","BDNF","Atrial Cardiomyopathy","2026-06-10",{"date":304,"type":40},{"date":182,"type":22},{"date":389,"type":22},"2029-07",{"name":391,"class":187},"Centre Hospitalier Universitaire Dijon",{"id":393,"slug":394,"hasResults":12,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":398,"eligibilityCriteria":399,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":400,"targetDuration":4,"studyType":23,"phases":401,"briefSummary":402,"conditions":403,"keywords":404,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":407,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":414},"100613542","phase-2-clinical-phase-2-trial-of-ap31969-versus-placebo-for-rhythm-control-of-atrial-fibrillation-100613542","NCT07267949","Clinical Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation","Clinical Randomised Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation","END-AF-1","Inclusion Criteria:\n\n* Willing and able to provide written informed consent.\n* Age 18 or older.\n* ECG documented diagnosis of paroxysmal or persistent AF.\n* AF history at screening indicating an expected AF burden of 1-90%, i.e., at least 1 self-terminating AF episode within 4 months prior to the screening visit.\n* AF burden of ≥ 1% and ≤ 90% assessed with an ECG patch device during the screening period prior to the randomisation visit.\n* Investigator and participant agreement to avoid non-trial related rhythm control intervention for the duration of the trial, including:\n\n  * Antiarrhythmic drug class I and\u002For III (including amiodarone)\n  * Electrical or pharmacological cardioversion\n  * AF ablation procedure\n* Willing to have a loop recorder implanted.\n\nExclusion Criteria:\n\n* Prior AF ablation procedure other than pulmonary vein isolation (PVI) only.\n* Any of the following events within 4 weeks prior to the screening visit: Myocardial infarction, Unstable angina pectoris, Stroke or transient, ischaemic attack, Percutaneous coronary intervention (PCI), Coronary artery bypass graft (CABG), Peripheral revascularisation procedure.\n* Cardiac pacing device e.g. pacemaker and cardiac resynchronization therapy device with atrial or ventricular pacing for \\> 5% of the time or existing implantable loop recorder.\n* Heart failure, New York Heart Association class III (3) or IV (4).\n* Left ventricular ejection fraction \\\u003C 40% based on imaging (e.g. echocardiography) performed within 6 months prior to or during the screening visit.\n* Clinically significant valvular heart disease, including severe aortic stenosis, severe mitral regurgitation and\u002For severe mitral stenosis, in the opinion of the investigator.\n* QTc (Fridericia, QTcF) interval \\> 450 ms for males and \\> 470 ms for females at screening.\n* eGFR \\\u003C60 mL\u002Fmin \u002F1.73 m² based on creatine and CKD-EPI formula\n* Use of antiarrhythmic drug class I and\u002For III within 7 days or, for amiodarone, within 3 months prior to the screening visit.",{"count":221,"type":22},[276],"A clinical Randomized Phase 2 Trial of AP31969 versus Placebo for Rhythm Control of Atrial Fibrillation.",[28],[67,405,406],"AP31969","SK channel inhibitor",{"date":362,"type":40},{"date":409,"type":40},"2025-10-22",{"date":411,"type":22},"2026-12",{"name":413,"class":47},"Acesion Pharma",44,{"id":416,"slug":417,"hasResults":12,"nctId":418,"briefTitle":419,"officialTitle":419,"acronym":420,"eligibilityCriteria":421,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":422,"targetDuration":4,"studyType":23,"phases":424,"briefSummary":425,"conditions":426,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":431,"completionDateStruct":432,"leadSponsor":434,"locationsCount":107},"100642910","exclusion-of-left-atrial-appendage-thrombus-in-emergency-department-patients-with-atrial-fibrillation-undergoing-ct-to-assess-for-pulmonary-embolus-a-feasibility-study-100642910","NCT07647939","Exclusion of Left Atrial Appendage Thrombus in Emergency Department Patients With Atrial Fibrillation Undergoing CT to Assess for Pulmonary Embolus: A Feasibility Study","ELATE-AF","Inclusion Criteria:\n\n* Patients above 18 years of age years deemed candidates for CT angiography for pulmonary embolism by the primary team on clinical grounds and noted to be in atrial fibrillation at the time.\n* Room air oxygen saturation above 92%\n* Systolic blood pressure above 100 mm Hg\n* Respiratory rate less than 24 breaths\u002Fmin\n\nExclusion Criteria:\n\n* Inability to personally give informed consent\n* Pregnant or breastfeeding individuals\n* Stroke like symptoms\n* ECG criteria for ischemia or infarction\n* Heart rate \\\u003C40 or \\> 120 bpm (inclusive) or 3rd degree heart block\n* Unable to lie flat for at least 10 minutes\n* Unable to follow simple commands\n* Northwell Health Employees.\n* Non-English-speaking patients",{"count":423,"type":22},60,[60],"This study aims to investigate whether a quick, additional CT scan of the heart, performed immediately after a standard CT scan for pulmonary embolism, can effectively detect blood clots in the left atrial appendage (LAA) in patients with atrial fibrillation. Detecting these clots is crucial before certain heart procedures to prevent stroke. Currently, a different, more involved procedure (Transesophageal Echocardiography - TEE) is often used. This study will assess if this additional CT scan is feasible, meaning if it can provide clear enough images to identify LAA clots without needing more contrast dye. The study will involve 60 patients, half receiving an \"ungated\" CT scan and the other half a \"gated\" CT scan (timed with their heart rhythm). The results of these scans will not be used for immediate patient care during the study, but rather to evaluate the CT scan technique itself. There is no direct benefit to participants, but the information gained could lead to faster diagnosis and reduced unnecessary testing for future patients.",[28,427,428],"Pulmonary Embolism (PE)","Left Atrial Appendage Thrombosis","2026-06-09",{"date":304,"type":40},{"date":182,"type":22},{"date":433,"type":22},"2027-06",{"name":435,"class":187},"Northwell Health",{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":444,"targetDuration":4,"studyType":23,"phases":446,"briefSummary":447,"conditions":448,"keywords":450,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":455,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":107},"100563611","evaluating-the-impact-of-home-based-sleep-apnea-diagnostic-on-well-being-health-behavior-and-af-load-in-patients-with-atrial-fibrillation-using-a-decentralized-platform-100563611","NCT06618417","Evaluating the Impact of Home-Based Sleep Apnea Diagnostic on Well-Being, Health Behavior, and AF Load in Patients With Atrial Fibrillation Using a Decentralized Platform","National Decentral\u002FVirtual Randomized Trial Testing Remote Sleep Apnea Evaluation in Patients With Atrial Fibrillation","VIR-SAAF","Inclusion Criteria:\n\n* Established paroxysmal or persistent AF diagnosis\n* Owning a compatible smartphone\n* 18 years or older\n\nExclusion Criteria:\n\n* Previous investigation for sleep-disturbed breathing\n* Advanced heart failure (left ventricular dysfunction and NYHA III\u002FIV)\n* Occupational driver licenses\n* Pregnancy\n* Doxazosin or Terazosin treatment (alpha-adrenergic antagonists)\n* Peripheral arterial disease with daily intermittent claudication",{"count":445,"type":22},936,[60],"The goal of this clinical trial is to find out if testing for sleep apnea (a condition where breathing stops and starts during sleep) at home can improve well-being in people with atrial fibrillation (an irregular heartbeat condition). About 936 participants will be involved. They will either be tested for sleep apnea and treated, if needed, or not tested at all.\n\nResearchers will compare the well-being and heart-related symptoms of participants who are tested for sleep apnea to those who are not. These will be tracked using a mobile app to monitor symptoms, physical activity, and heart rhythm.\n\nMain hypothesis: Participants with atrial fibrillation who are tested and possibly treated for sleep apnea will have improved quality of life scores (measured by the Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) questionnaire) by at least 5 points after 18 weeks.",[28,449],"Sleep Apnea",[35,451,452,31,453,454],"decentralized","sleep apnea home-evaluation","digital health","quality of life",{"date":385,"type":40},{"date":457,"type":40},"2024-12-05",{"date":459,"type":22},"2027-06-30",{"name":461,"class":187},"Herlev and Gentofte Hospital",{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":466,"acronym":467,"eligibilityCriteria":468,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":469,"targetDuration":4,"studyType":23,"phases":471,"briefSummary":472,"conditions":473,"keywords":475,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":482,"completionDateStruct":484,"leadSponsor":486,"locationsCount":164},"100593131","left-atrial-imaging-prior-to-cardioversion-leveraging-computed-tomography-to-rule-out-thrombus-in-the-emergency-department-la-clotted-100593131","NCT07002450","Left Atrial Imaging Prior to Cardioversion: Leveraging Computed Tomography to Rule Out Thrombus in The Emergency Department (LA CLOTTED)","LA CLOTTED","Inclusion Criteria:\n\n1. Age ≥18 years old; and\n2. Primary symptomatic AF without a reversible underlying cause (e.g. sepsis, pneumonia, pulmonary embolism, hyperthyroidism)\n3. LA imaging required before cardioversion according to local clinical practice guidelines\n\nExclusion Criteria:\n\n1. Patients with an indication for emergency cardioversion (e.g. hemodynamic instability (systolic blood pressure\\\u003C90mmHg or signs of shock), cardiac ischemia (ongoing severe chest pain or marked ST depression on ECG \\>2mm), or pulmonary edema (significant dyspnea, crackles, or hypoxia)); or\n2. Contraindication to CCT (renal insufficiency (eGFR\\\u003C 45ml\u002Fmin\u002F1.73m2), allergy to intravenous contrast agents, pregnancy (contraindications to radiation exposure), or inability to perform 20-second breath-hold)",{"count":470,"type":22},190,[60],"The goal of this randomized clinical trial is to learn whether patients with symptomatic atrial fibrillation or atrial flutter (AF) who require heart imaging to rule out a blood clot before cardioversion would benefit from cardiac computed tomography angiography (CCT) in the emergency department (ED) compared to current standard of care management.\n\nThis will be a multicenter trial evaluating whether CCT-facilitated cardioversion in the ED reduces hospital admission, reduces repeat presentations to hospital and improves patient quality of life compared to the current standard of care.\n\nParticipants will undergo CCT-facilitated cardioversion or be treated according to current standard of care while in the ED and complete quality of life questionnaires in the ED and follow-up at 30 days.",[28,474],"Atrial Flutter",[476,477,478,479],"Cardiac computed tomography angiography","Cardioversion","Atrial flutter","Atrial fibrillation","2026-06-08",{"date":429,"type":40},{"date":483,"type":40},"2025-06-15",{"date":485,"type":22},"2028-06-15",{"name":487,"class":187},"Ottawa Heart Institute Research Corporation",{"id":489,"slug":490,"hasResults":12,"nctId":491,"briefTitle":492,"officialTitle":493,"acronym":494,"eligibilityCriteria":495,"healthyVolunteers":12,"sex":18,"minAge":496,"maxAge":497,"enrollmentInfo":498,"targetDuration":4,"studyType":23,"phases":500,"briefSummary":501,"conditions":502,"keywords":503,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":516,"locationsCount":518},"100643143","prediction-of-atrial-fibrillation-using-polygenic-risk-score-100643143","NCT07641582","Prediction of Atrial Fibrillation Using Polygenic Risk Score","Development of an Atrial Fibrillation Prediction Model Using Polygenic Risk Score: A Prospective Cohort Study","PREGENCE","Inclusion Criteria:\n\n* Patients with symptoms suggestive of paroxysmal atrial fibrillation, such as intermittent palpitations or chest discomfort\n* Asymptomatic patients aged 60 or older with at least one of the following risk factors for atrial fibrillation: hypertension, diabetes, coronary artery disease, valvular heart disease, cardiomyopathy, sleep apnea, hyperthyroidism, obesity (BMI greater than 30), or chronic alcohol dependence (drinking more than 3 times per week)\n\nExclusion Criteria:\n\n* Age under 20 years or over 80 years\n* Moderate or severe cognitive impairment\n* Previously diagnosed with atrial fibrillation prior to study enrollment\n* Does not consent to participate in the study","20 Years","79 Years",{"count":499,"type":22},800,[60],"The goal of this clinical trial is to learn whether a genetic risk score can help identify undiagnosed atrial fibrillation (AF) in adults who may have it. AF is an irregular heartbeat that raises the risk of stroke if not treated early.\n\nThe main questions it aims to answer are:\n\nCan a polygenic risk score (PRS) - a score based on a person's genes - identify who is more likely to have AF? Does combining PRS with a person's medical history predict AF better than using medical history alone?\n\nParticipants will:\n\nWear a continuous ECG patch for 7 days to record heart rhythm Give a blood sample for genetic testing to calculate their PRS Use a six-lead handheld ECG device (HATIV® P30, VUNO Inc., Seoul, Republic of Korea) to check their own heart rhythm at home once or twice a week for 1 year Visit the clinic 5 times over 1 year\n\nResearchers will use the genetic and clinical information collected to build a scoring system that predicts who is at risk for AF.",[28],[504,505,506,507,508,509],"Polygenic Risk Score","Atrial Fibrillation Screening","Handheld ECG","SNP Array","Holter Monitoring","Genetic Risk","2026-06-06",{"date":512,"type":40},"2026-06-11",{"date":514,"type":40},"2024-11-19",{"date":459,"type":22},{"name":517,"class":187},"Seoul St. Mary's Hospital",5,{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":525,"eligibilityCriteria":526,"healthyVolunteers":12,"sex":18,"minAge":320,"maxAge":4,"enrollmentInfo":527,"targetDuration":4,"studyType":23,"phases":528,"briefSummary":529,"conditions":530,"keywords":535,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":539,"completionDateStruct":541,"leadSponsor":543,"locationsCount":107},"100626880","catheter-ablation-plus-laao-versus-anticoagulation-in-frail-elderly-patients-with-atrial-fibrillation-100626880","NCT07441382","Catheter Ablation Plus LAAO Versus Anticoagulation in Frail Elderly Patients With Atrial Fibrillation","Randomized Controlled Trial - Catheter Ablation Combined With Left Atrial Appendage Occlusion Versus Catheter Ablation Combined With Oral Anticoagulation for Elderly Frailty Patients With Atrial Fibrillation: Comparison of Efficacy and Safety","CLEAR-AF","Inclusion Criteria: (1) Age ≥ 75 years. (2) Confirmed diagnosis of non-valvular atrial fibrillation (paroxysmal or persistent). (3) CHA2DS2-VASc score ≥ 3 (high risk of stroke) . (4) Procedure-related criteria: Sequential Group: Participants who have received catheter ablation for non-valvular AF within 90 to 180 days prior to randomization. One-stop Group: Participants who are scheduled to undergo clinically indicated catheter ablation within 10 days after randomization. (5) Judged by the investigator to be able to tolerate the defined antithrombotic drug regimen. (6) Suitable to undergo Transesophageal Echocardiography (TEE) or Pulmonary Vein Computed Tomography (CT). (7) Able and willing to sign the written informed consent form. (8) Willing to return for all scheduled follow-up visits and examinations. Exclusion Criteria: (1) Presence of thrombus in the left atrium or left atrial appendage identified on preoperative imaging (echocardiogram, pulmonary vein CT, etc). (2) Major bleeding event (per ISTH definition) within 14 days prior to randomization. Participants must be excluded if clinical sequelae persist or if interventions for the bleeding source are planned\u002Fpending, regardless of the time elapsed since the event. (3) Requirement for long-term oral anticoagulation (OAC) for reasons other than stroke risk reduction in AF (e.g., underlying hypercoagulable state) that would prevent OAC discontinuation post-device implantation. (4) Any cardiac or major non-cardiac intervention\u002Fsurgery (excluding AF ablation and cardioversion) performed within 30 days prior to, or scheduled within 60 days after randomization. This includes but is not limited to Percutaneous Coronary Intervention (PCI) or other cardiac ablations. (5) Life expectancy \\\u003C 2 years, malignancy, infectious endocarditis, uncontrolled infection, or physiological evidence of cardiac tamponade. (6) Clinical Frailty Scale (CFS) score of 1-3 (not frail) or 7-9 (severely frail\u002Fterminally ill). (7) Deemed unsuitable for long-term anticoagulation and\u002For antiplatelet therapy by the investigator due to bleeding risk, allergies, or other reasons. (8) Current participation in another clinical trial that interferes with this study, excluding mandatory government or purely observational registries. (9) Stroke or transient ischemic attack (TIA) within 60 days prior to randomization. (10) Documented myocardial infarction (NSTEMI or STEMI) within 90 days prior to randomization, regardless of intervention. (11) History of atrial septal defect (ASD) repair or presence of an ASD\u002FPatent Foramen Ovale (PFO) occluder. (12) Presence of a mechanical prosthetic valve in any position. (13) Participants of childbearing potential who are pregnant or planning pregnancy during the study period. (14) Medical or anatomical contraindications to percutaneous catheter-based interventions. (15) Documented NYHA Class IV heart failure. (16) History of surgical left atrial appendage (LAA) closure.\n\nTransthoracic Echocardiography (TTE) Specific Exclusions: (1) Low LVEF: Left ventricular ejection fraction (LVEF) \\\u003C 30%. (2) Presence of pericardial effusion with a circumferential echo-free space \\> 5mm. (3) Presence of high-risk PFO associated with an atrial septal aneurysm (ASA) with an excursion or length \\> 15mm. (4) Presence of high-risk PFO with a large shunt (defined as appearance of microbubbles within 3 cardiac cycles and\u002For a substantial count of microbubbles). (5) Presence of moderate or severe mitral stenosis (mitral valve area \\\u003C 1.5 cm2).",{"count":221,"type":22},[60],"Atrial fibrillation (AF) is the most common arrhythmia, significantly increasing the risk of stroke, heart failure, hospitalization and death in patients. Studies have shown that standardized anticoagulation can effectively reduce the risk of stroke by 64% and the risk of death by 26% in AF patients. Therefore, both European and American guidelines recommend standardized oral anticoagulation (OAC) as an important treatment strategy for stroke prevention in AF patients. However, the use of OAC may also increase the risk of bleeding in patients. Results from large AF anticoagulation randomized trials show that the annual risk of anticoagulation-related bleeding mortality is 2% to 3%. Therefore, according to the guidelines recommendations, assessing the bleeding risk is necessary in patients with anticoagulant indications.\n\nPercutaneous left atrial appendage occlusion (LAAO) is a device-based therapy that aims to prevent ischemic stroke in patients with AF. For patients with contraindications to long-term anticoagulation therapy, LAAO can be considered as an alternative strategy to oral anticoagulation (Class II B recommendation) to prevent ischemic stroke and thromboembolism. Multiple studies have shown that LAAO is non-inferior to warfarin and novel oral anticoagulants in stroke prevention for non-valvular AF patients. Age is not only a risk factor for stroke but also an important risk factor for bleeding. In the elderly population, especially those with frailty, the risk factors for both stroke and bleeding are often increased. Currently, there is insufficient evidence to support the use of OAC in frail elderly patients with relative anticoagulant contraindications. Therefore, elderly AF patients may be one of the potential beneficiary groups for LAAO. However, most previous clinical studies on LAAO were based on small sample sizes to analyze their safety and efficacy, and clinical data on the safety and efficacy of LAAO in this high-risk population of elderly AF patients are still limited. To address this, the study aims to conduct a multicenter randomized controlled trial to compare the efficacy and safety of catheter ablation combined with LAAO versus catheter ablation combined with OAC in elderly AF patients with high bleeding risk, filling the gap in this research area.\n\nTo address these limitations, this multicenter randomized controlled trial is designed to evaluate the efficacy and safety of catheter ablation combined with LAAO versus catheter ablation combined with OAC in elderly AF patients at high risk for bleeding. The primary objective of the study is to compare the 12-month incidence and time-to-occurrence of the composite clinical endpoint. This endpoint includes stroke\u002FTIA, systemic embolism, ISTH-defined major bleeding. By establishing these metrics within the first year, the study aims to fill the current void in clinical evidence and provide a standardized treatment strategy for high-risk elderly patients. In addition to the primary endpoints, the study will conduct a comprehensive long-term evaluation extending to 24 months post-procedure to assess the durability of both treatment strategies. Secondary objectives include the assessment of perioperative safety, specifically focusing on serious intraoperative complications and major adverse events occurring within the first seven days after the LAAO procedure. The trial will also measure long-term rhythm control by tracking the rate of freedom from AF recurrence at the one-year and two-year marks. Furthermore, the study seeks to verify the hypothesized superiority of the ablation-plus-LAAO strategy in reducing the specific burden of anticoagulation-related major bleeding and stroke.\n\nBeyond clinical safety and efficacy, the trial will analyze the practical aspects of the two interventions, including procedural success rates, operation duration, fluoroscopy time, and the total duration of hospitalization. A critical component of the research involves identifying specific risk factors associated with complications, with a specialized focus on how frailty scores influence procedural tolerance and long-term prognosis. The study will further explore how different types of AF respond to the LAAO strategy and assess the impact of each treatment on non-major bleeding events. Ultimately, the trial aims to determine which strategy offers a superior improvement in the overall quality of life for elderly patients, thereby optimizing future clinical guidelines.",[28,281,531,532,533,335,534],"Hemorrhage","Frailty","Atrial Appendage","Anticoagulants",[67,149,281,531,534,532,536,205,335],"Aged","2026-06-05",{"date":480,"type":40},{"date":540,"type":40},"2026-03-24",{"date":542,"type":22},"2028-03-01",{"name":544,"class":187},"Guangdong Provincial People's Hospital",{"id":546,"slug":547,"hasResults":12,"nctId":548,"briefTitle":549,"officialTitle":549,"acronym":550,"eligibilityCriteria":551,"healthyVolunteers":12,"sex":18,"minAge":552,"maxAge":4,"enrollmentInfo":553,"targetDuration":4,"studyType":23,"phases":554,"briefSummary":555,"conditions":556,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":558,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":563,"locationsCount":107},"100528748","cardiac-arrhythmia-telemetry-conventional-vs-heartwatch-100528748","NCT06164808","Cardiac Arrhythmia Telemetry; Conventional vs HeartWatch","CATCH","Inclusion Criteria:\n\n* At least 22 years of age at time of consent\n* Clinically indicated for a Holter monitor test\n* Able to wear the HeartWatch on the left bicep for the study duration\n* Able to follow the protocol\n* No functional implantable pacemaker or defibrillator\n* Left bicep circumference \\>\u002F= 22 cm and \\\u003C\u002F= 45 cm\n* Provision of written-informed consent\n\nExclusion Criteria:\n\n* Known allergy to any component of the Holter monitor\n* Known allergy to any component of the HeartWatch\n* Inability to wear the HeartWatch on the left arm for the study period due to pre-existing medical condition (3.g., functional AV fistula in left arm, prior carcinoma with lymph node dissection or lymphedema, known blood clot of recurrent blood clots in the left arm, chronic neuropathic pain in left arm, ...)\n* Dextrocardia\n* Implanted functional Pacemaker or Defibrillator\n* Left bicep circumference \\\u003C 22 cm\n* Left bicep circumference \\\u003C 45 cm","22 Years",{"count":353,"type":22},[60],"Heart rhythm disorders are common and significantly impact the lives of those affected and their families. The main problems can be categorized as: a) atrial fibrillation or AF and atrial flutter, b) supra-ventricular tachycardia or SVT, c) excessively slow heart beats (i.e., bradycardia or pauses) and d) ventricular arrhythmias. These problems can be difficult to detect with currently available monitoring options as they are all worn for shorter terms or are an invasive implantable option. The HeartWatch is a longer term monitoring system that is worn on the upper arm, allows users to create a tag and pairs with an app on a smartphone allowing for correlation of symptoms.",[381,557,28],"Diagnostic\u002FMonitoring Devices Related to Adverse Incidents",{"date":429,"type":40},{"date":560,"type":40},"2024-02-20",{"date":562,"type":22},"2026-12-31",{"name":564,"class":47},"HelpWear Inc.",{"id":566,"slug":567,"hasResults":12,"nctId":568,"briefTitle":569,"officialTitle":570,"acronym":571,"eligibilityCriteria":572,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":320,"enrollmentInfo":573,"targetDuration":4,"studyType":23,"phases":575,"briefSummary":576,"conditions":577,"keywords":579,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":583,"startDateStruct":584,"completionDateStruct":585,"leadSponsor":587,"locationsCount":164},"100643817","the-combine-af-trial-100643817","NCT07633509","The COMBINE-AF Trial","A Multicenter, Prospective, Randomized Controlled Trial of Combined Pulsed-Field and Radiofrequency-Modified Linear Ablation Versus Pulsed-Field Ablation Alone for Long-Standing Persistent Atrial Fibrillation","COMBINE-AF","Inclusion Criteria:\n\n* Symptomatic patients with long-standing persistent atrial fibrillation.\n* Duration of atrial fibrillation between 1 and 3 years.\n* Age 18 to 75 years.\n* Left atrial diameter between 43 mm and 55 mm.\n* Documentation of atrial fibrillation within 3 years prior to enrollment.\n* Willing and able to comply with the study protocol and provide written informed consent.\n\nExclusion Criteria:\n\n* Paroxysmal atrial fibrillation, or evidence of sinus rhythm on electrocardiogram within the past year.\n* Persistent atrial fibrillation lasting less than 1 year or more than 3 years.\n* Left atrial thrombus.\n* Prior catheter ablation for atrial fibrillation.\n* Coexisting severe organic heart disease (e.g., severe valvular heart disease, hypertrophic cardiomyopathy, dilated cardiomyopathy, etc.).\n* Left atrial diameter (LAD) \\>55 mm.\n* Left ventricular ejection fraction (LVEF) \\\u003C40%.\n* Known allergy or contraindication to low-molecular-weight heparin, warfarin, or direct oral anticoagulants.\n* Undergoing a \"one-stop\" procedure combining atrial fibrillation ablation with left atrial appendage closure.\n* Allergy to alcohol or contrast media.\n* Pulmonary artery systolic pressure \\>50 mmHg.\n* Unstable angina pectoris.\n* Percutaneous coronary intervention (PCI) within the past 3 months.\n* Cardiac surgery within the past 6 months.\n* Planned heart transplantation.\n* History of thromboembolic disease within the past 6 months (including venous thromboembolism: pulmonary embolism, deep vein thrombosis; or arterial thromboembolic disease: acute coronary syndrome, lower extremity arterial embolism, stroke).\n* Left atrial myxoma.\n* Severe respiratory disease.\n* Active infectious disease.\n* Poorly controlled or active systemic immune disease (equivalent to glucocorticoid use \\>2 tablets\u002Fday).\n* Unresolved malignant hematologic disease, or currently receiving chemotherapy, radiotherapy, or immunotherapy.\n* Unresolved malignant solid tumor, or currently receiving chemotherapy, radiotherapy, or immunotherapy.\n* Untreated hypothyroidism or hyperthyroidism.\n* Severe hepatic insufficiency (alanine aminotransferase \\[ALT\\] or aspartate aminotransferase \\[AST\\] \\>3 times the upper limit of normal).\n* End-stage renal failure requiring dialysis.\n* Other serious arrhythmias, such as hemodynamically unstable ventricular tachycardia.\n* Pregnancy or breast-feeding.\n* Psychiatric disorder.\n* Body mass index (BMI) \\\u003C18.5 or \\>35.0 kg\u002Fm².\n* Life expectancy \\\u003C2 years.",{"count":574,"type":22},430,[60],"The goal of this clinical trial is to test if a more complete ablation procedure works better than the standard procedure for people with long-lasting atrial fibrillation (AF). AF is a heart rhythm problem that can cause a fast or uneven heartbeat.\n\nThis study will include 430 people with long-lasting AF that has lasted 1 to 3 years. Participants will be put into one of two groups by chance:\n\nFirst group (control): They will receive pulsed-field ablation (PFA), a type of energy that can stop the faulty heart signals. They will have isolation of the pulmonary veins and the back wall of the left atrium.\n\nSecond group (study): They will receive the same PFA procedure plus extra ablation lines (modified linear ablation) using radiofrequency energy. This includes ablation of the mitral isthmus (with ethanol infusion into a small vein called the vein of Marshall) and the cavotricuspid isthmus.\n\nParticipants will be followed for 12 months after the procedure with clinic visits, electrocardiograms (ECGs), and heart rhythm monitors. The main outcome is whether participants stay in normal heart rhythm (sinus rhythm) without any AF episodes lasting more than 30 seconds at 12 months. Researchers will also look at procedure time, complication rates, quality of life, and other rhythm outcomes.\n\nThis study will help show if the more complete ablation procedure leads to better long-term results for people with long-lasting AF.",[28,578],"Atrial Fibrillation Catheter Ablation",[67,335,580,90,581],"Long-standing Persistent Atrial Fibrillation","Radiofrequency Ablation","2026-06-04",{"date":480,"type":40},{"date":304,"type":22},{"date":586,"type":22},"2029-12-31",{"name":588,"class":187},"Yunlong Wang",{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":593,"acronym":594,"eligibilityCriteria":595,"healthyVolunteers":596,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":597,"targetDuration":4,"studyType":23,"phases":599,"briefSummary":600,"conditions":601,"keywords":602,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":606,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":610,"locationsCount":107},"100572571","identification-of-the-metabolic-signature-of-atrial-fibrillation-for-personalized-prevention-100572571","NCT06735001","Identification of the Metabolic Signature of Atrial Fibrillation for Personalized Prevention","IMAGE-AF","Inclusion Criteria:\n\n* Age ≥ 18 years, all genders, and ethnic origins\n* Free, informed, and written consent signed\n* Person affiliated to or benefiting from a social security scheme\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Lack of informed consent\n* Gestating women (pregnancy test carried out as part of care for FA patients, contraception, or menopause for women in control groups)\n* Persons under administrative or judicial protection\n* Endocarditis or pericarditis in progress or within the 3 last months\n* Active tumor pathology (benign or malignant)\n* Chronic inflammation or autoimmune disease\n* Chronic liver disease\n* Myocardial infarction within the last 8 weeks",true,{"count":598,"type":22},400,[60],"Atrial fibrillation (AF) is a major public health problem. The efficacy of the existing techniques is limited in the more aggressive forms. It is therefore necessary to develop approaches, in particular the identification of relevant biomarkers, to prevent the onset, recurrence or progression of AF in at-risk patients. The objective of this study is to describe the longitudinal metabolic and biomolecular signature of AF in patients eligible for cardiac ablation.",[28],[35,603,604,605],"prevention","biomarkers","cardiac metabolism",{"date":429,"type":40},{"date":608,"type":40},"2025-03-10",{"date":367,"type":22},{"name":611,"class":187},"University Hospital, Bordeaux",{"id":613,"slug":614,"hasResults":12,"nctId":615,"briefTitle":616,"officialTitle":617,"acronym":618,"eligibilityCriteria":619,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":299,"enrollmentInfo":620,"targetDuration":4,"studyType":23,"phases":622,"briefSummary":623,"conditions":624,"keywords":625,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":630,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":635,"locationsCount":344},"100576374","coherent-sine-burst-electroporation-cse-ablation-system-us-ide-study-for-patients-with-atrial-fibrillation-100576374","NCT06784466","Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation","Coherent Sine Burst Electroporation (CSE) Ablation System US Investigational Device Exemption (IDE) Study for Patients With Atrial Fibrillation","COHERENT-AF","Inclusion Criteria:\n\n1. Patients between the ages of 18 and 80 years, or older than 18 if required by local law.\n2. Diagnosis of drug refractory, recurrent, paroxysmal or persistent AF:\n\n   a. Symptomatic paroxysmal AF that is less than 7 days in continuous duration, documented by the following: i. Physician documentation of symptomatic recurrent PAF (2 or more episodes) within 6 months prior to enrollment AND ii. At least 1 documented AF episode from any form of rhythm monitoring within 12 months prior to enrollment.\n\n   b. Symptomatic persistent AF that is sustained beyond 7 days and less than 1 year (≥ 7 and ≤ 365 days), documented by the following: i. Physician documentation of at least 1 symptomatic persistent AF episode within 6 months prior to enrollment.\n\n   ii. Either a 24-hour continuous ECG recording documenting continuous AF OR 2 ECGs from any regulatory cleared rhythm monitoring device showing continuous AF taken at least 7 days apart, within 6 months prior to enrollment.\n3. Effectiveness failure of, intolerance to, or a specific contraindication to at least one Class I or III anti-arrhythmic drug.\n4. Willing and able to give informed consent.\n5. Willingness, ability, and commitment to participate in baseline, follow-up, and rhythm monitoring evaluations for the full length of the study.\n6. Life expectancy \\>1 year.\n\nExclusion Criteria:\n\n1. In the opinion of the Investigator, any known contraindication to an AF ablation (including present left atrial \\[LA\\] thrombus), trans-esophageal echocardiogram (TEE) or computed tomography (CT) scan, or anticoagulation.\n2. Any duration of continuous AF lasting longer than 12 months.\n3. History of any previous left atrial ablation or surgical procedure, including prior left atrial appendage closure.\n4. AF secondary to electrolyte imbalance, thyroid disease, alcohol, or any other reversible or non-cardiac cause.\n5. Left ventricular ejection fraction (LVEF) \\\u003C 35% within 6 months of enrollment (e.g. transthoracic echocardiogram (TTE), multiple-gated acquisition (MUGA), magnetic resonance imaging (MRI), nuclear stress test).\n6. New York Heart Association (NYHA) Class III or IV.\n7. Left atrial diameter \\> 5.0 cm (anteroposterior) within 6 months of enrollment (MRI, CT, TTE, TEE, or physician's note) or non-indexed volume \\>100mL if left atrial diameter is not available.\n8. Current or anticipated implant of a permanent pacemaker, implantable cardioverter or resynchronization device, interatrial baffle, foramen ovale occluder, LA appendage closure, or active implantable\u002Finsertable cardiac loop recorder\u002Fmonitor at the time of the ablation procedure.\n9. Body mass index (BMI) \\>40.\n10. Patients who have not been on anticoagulation therapy for at least 3 weeks prior to the Index Procedure.\n11. Previous cardiac surgery, myocardial infarction, percutaneous coronary intervention or angioplasty (PCI\u002FPTCA) or coronary artery stenting within 3 months prior to enrollment.\n12. Symptomatic valvular disease, history of cardiac valve surgery, or prosthetic mitral and tricuspid valve(s).\n13. Presence of pulmonary vein abnormalities of stenosis or stenting.\n14. Primary pulmonary hypertension.\n15. Uncontrolled or untreated hypertension (two measurements of \\>180mmHg systolic or \\>110 mmHg diastolic at baseline).\n16. Pre-existing hemi-diaphragmatic paralysis.\n17. Renal insufficiency with an estimated glomerular filtration rate (eGFR) \\\u003C 40 mL\u002Fmin\u002F1.73 m2, or any history of renal dialysis or renal transplant.\n18. Rheumatic heart disease.\n19. Unstable angina or ongoing myocardial ischemia.\n20. Hypertrophic cardiomyopathy, advanced restrictive cardiomyopathy, or severe left ventricular hypertrophy (left ventricular thickness \\>15mm).\n21. History of blood clotting or bleeding disease (e.g., thrombocytosis).\n22. History of documented cerebral infarction, transient ischemic attack, or systemic embolism within 6 months prior to enrollment.\n23. Active systemic infection.\n24. Active malignancy or history of treated malignancy within 12 months of enrollment (other than cutaneous basal cell or squamous cell carcinoma, or non-metastatic prostate or breast cancer with life expectancy remaining \\>1 year).\n25. Pregnant or lactating (current or anticipated during study follow-up).\n26. Current enrollment in any other clinical study where testing or results from that study may interfere with the procedure or outcomes measurement for this study.\n27. Any other condition that, in the judgment of the Investigator, makes the patient:\n\n    1. Unlikely to benefit from an AF ablation procedure (e.g., advanced infiltrative cardiomyopathies, severe mitral stenosis or regurgitation, and\u002For cor pulmonale, etc.), or\n    2. A poor candidate for the study (e.g., vulnerable patient population, mental illness, addictive disease, terminal illness, and extensive travel away from the research center).",{"count":621,"type":22},360,[60],"To evaluate the safety and effectiveness of the Argá Medtech CSE Ablation System in the treatment of atrial fibrillation.",[28,121,63],[35,626,627,628,629],"ablation","coherent sine-burst","electroporation","pulsed field ablation",{"date":537,"type":40},{"date":632,"type":40},"2025-09-10",{"date":634,"type":22},"2027-08",{"name":636,"class":47},"Arga Medtech SA",{"id":638,"slug":639,"hasResults":12,"nctId":640,"briefTitle":641,"officialTitle":642,"acronym":643,"eligibilityCriteria":644,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":645,"targetDuration":647,"studyType":176,"phases":4,"briefSummary":648,"conditions":649,"keywords":651,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":654,"lastUpdatePostDateStruct":655,"startDateStruct":656,"completionDateStruct":658,"leadSponsor":660,"locationsCount":661},"100594859","complex-arrhythmia-registry-100594859","NCT07024927","Complex Arrhythmia Registry","Complex Arrhythmia Registry（CAR）： Long-term Outcomes of Catheter Ablation for Atrial Fibrillation or Ventricular Tachycardia： A Multicenter， Prospective Cohort Study","CAR","1. Atrial Fibrillation (AF) Cohort:\n\n   * Inclusion Criteria (Patients must meet ALL of the following criteria):\n\n     1. Age ≥ 18 years.\n     2. Diagnosed with atrial fibrillation (AF), including paroxysmal AF (PAF) and persistent AF (PsAF).\n     3. Scheduled to undergo first-time catheter ablation for AF.\n     4. Procedure to be performed using a 3D mapping system.\n     5. Provision of signed written informed consent for study participation and willingness and ability to comply with all protocol-required follow-up assessments.\n   * Exclusion Criteria (Patients meeting ANY of the following criteria will be excluded):\n\n     1. Severe congenital heart disease (e.g., Tetralogy of Fallot, corrected transposition of the great arteries).\n     2. AF secondary to a clearly reversible cause (e.g., hyperthyroidism, post-operative state, acute alcohol intoxication).\n     3. Unstable angina pectoris or acute myocardial infarction (MI) within 30 days prior to enrollment\u002Fprocedure.\n     4. Severe active infection (e.g., septic shock, sepsis).\n     5. Contraindications to anticoagulation therapy.\n     6. Current participation in another interventional clinical trial that may confound the results of this study.\n     7. Any other condition where, in the investigator's judgment, the patient is unsuitable for participation in this study.\n2. Ventricular Tachycardia (VT) Cohort\n\n   * Inclusion Criteria (Patients must meet ALL of the following criteria):\n\n     1. Age ≥ 18 years.\n     2. Diagnosed with ventricular tachycardia (VT) associated with underlying structural heart disease, including:\n     3. Ischemic heart disease (e.g., prior MI, coronary artery disease).\n     4. Non-ischemic cardiomyopathy (e.g., dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), hypertrophic cardiomyopathy (HCM)).\n     5. Scheduled to undergo first-time catheter ablation for VT.\n     6. Procedure to be performed using a 3D mapping system.\n     7. Provision of signed written informed consent for study participation and willingness and ability to comply with all protocol-required follow-up assessments.\n   * Exclusion Criteria (Patients meeting ANY of the following criteria will be excluded):\n\n     1. VT due to a transient or reversible cause (e.g., acute myocardial ischemia, severe electrolyte imbalance).\n     2. Idiopathic ventricular tachycardia (VT occurring in the absence of structural heart disease).\n     3. Cardiac surgery within 60 days prior to the planned ablation procedure.\n     4. Severe coagulopathy (e.g., platelet count \\\u003C 50 x 10⁹\u002FL, disseminated intravascular coagulation (DIC)).\n     5. Severe heart failure with left ventricular ejection fraction (LVEF) \\\u003C 20%.\n     6. Severe active infection (e.g., septic shock, sepsis).\n     7. Current participation in another interventional clinical trial that may confound the results of this study.\n     8. Any other condition where, in the investigator's judgment, the patient is unsuitable for participation in this study.",{"count":646,"type":22},4000,"3 Years","This is a prospective, non-randomized, multicenter observational registry study designed to systematically evaluate the long-term efficacy and safety of catheter ablation for treating atrial fibrillation (AF) and ventricular tachycardia (VT) in Chinese patients.",[28,650],"Ventricular Tachycardia (VT)",[35,652,626,653],"ventricular tachycardia","registry study","2026-06-02",{"date":582,"type":40},{"date":657,"type":40},"2025-10-21",{"date":659,"type":22},"2032-06",{"name":343,"class":187},2]